PRA Health Sciences

PRA Health Sciences is a full-service global contract research organization providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. PRA Health Sciences' global operations span more than 90 offices across North America, Europe, Asia, Latin America, South Africa, Australia, and the Middle East. PRA’s 17,000+ employees have participated in more than 3,800 clinical trials and have supported pivotal trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 85 products since the year 2000.

Allscripts Healthcare Solutions

CHICAGO--(BUSINESS WIRE)---- $MDRX #healthIT--Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), and PRA Health Sciences, Inc. (NASDAQ: PRAH), one of the world's leading global contract research organizations, announced today the creation of the industry's leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States. Using V

Veradigm and PRA Health Sciences Partner to Create the Industry's Leading EHR-Based Clinical Research Network

RALEIGH, N.C.--(BUSINESS WIRE)-- #bha--Veranex today announced the formation of the first concept-to-commercialization global service provider dedicated to the medtech industry.

Veranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services Company

Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.

Here's Why You Should Retain PRA Health (PRAH) Stock for Now

PRA Health's (PRAH) tokenization solution can help in the generation of enhanced evidence for drug development through Synoma.

PRA Health's (PRAH) New Solution to Speed Up Drug Development

Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act. Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act.

PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the first quarter.

PRA Health (PRAH) Stock Down 0.3% Despite Q1 Earnings Beat

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of PRA Health Sciences, Inc. (NasdaqGS: PRAH) to -ICON plc, (NasdaqGS: ICLR). Under the terms of the proposed transaction, shareholders of PRA will receive only $80 in cash and 0.4125 shares of ICON stock for each share of PRA that they own. KSF is seeking to determine whether this consideration and the process t

PRA HEALTH SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PRA Health Sciences, Inc. - PRAH

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 0.75% and 9.22%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

PRA Health Sciences (PRAH) Q1 Earnings and Revenues Beat Estimates

Shares of PRA Health Sciences (NASDAQ:PRAH) fell after the company reported Q1 results. Quarterly Results Earnings per share were up 28.57% year over year to $1.35, which beat the estimate of $1.34.

Recap: PRA Health Sciences Q1 Earnings

RALEIGH, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended March 31, 2021.

PRA Health Sciences, Inc. Reports First Quarter 2021 Results

Hologic

PerkinElmer

Here we discuss three MedTech subsectors, which encourage us with their consistency through the pandemic year and are likely to have continued with their winning streak in Q121.

3 MedTech Subsectors Poised to Perform Impressively in Q121

PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRA Health Sciences (PRAH) Earnings Expected to Grow: Should You Buy?

PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and therapeutic pharmacovigilance requirements PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and therapeutic pharmacovigilance requirements

PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics

Align Technology

ICON

STERIS

Teladoc

Thermo Fisher Scientific

DENTSPLY SIRONA

While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.

MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth

PRA Health Sciences (PRAH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

PRA Health Sciences (PRAH) Surges 3.8%: Is This an Indication of Further Gains?

PRA Health's (PRAH) company, Care Innovations, gets selected by MedChi to provide remote patient monitoring services, thereby enabling better patient care.

PRA Health (PRAH) Chosen by MedChi to Offer Telehealth Services

Maryland-based physicians can quickly deploy remote care options for patients with PRA's digital health technology Maryland-based physicians can quickly deploy remote care options for patients with PRA's digital health technology

PRA Health Sciences selected by Maryland State Medical Society to supply remote patient monitoring and telehealth services

Merck

PRA Health's (PRAH) remote patient monitoring platform will enable Merck KGaA to offer patients an array of advanced tools to help manage their conditions.

Merck KGaA Chooses PRA Health's (PRAH) Remote Monitoring Tool

PRA's cloud-based infrastructure enables Merck KGaA, Darmstadt, Germany to deliver a better product experience and scale for future enhancements PRA's cloud-based infrastructure enables Merck KGaA, Darmstadt, Germany to deliver a better product experience and scale for future enhancements

PRA's remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human growth hormone treatment system

PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock?

Why Is PRA Health Sciences (PRAH) Down 0.7% Since Last Earnings Report?

PRA Health (PRAH) launches patient-focused toolkit to lower the burden on patients with rare diseases to participate in clinical research.

PRA Health (PRAH) Unveils Toolkit for Rare Disease Patients

Four-part, patient-focused toolkit is available for download at no cost and allows sponsors to identify risks to the efficiency and success of their trials Four-part, patient-focused toolkit is available for download at no cost and allows sponsors to identify risks to the efficiency and success of their trials

PRA's Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical Programs

Michaels

Severn Bancorp

Talend SA

WSFS Financial

NEW YORK, March 11, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: PRA Health Sciences, Inc. (NASDAQ: PRAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ICON plc. Under the terms of the transaction, PRA Health shareholders will receive $80.00 in cash and 0.4125 shares of ICON stock for each PRA Health share that they own.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRAH, MIK, WSFS, TLND, SVBI; Shareholders are Encouraged to Contact the Firm

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.

PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat

NEW YORK, Feb. 27, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...

News for PRA Health Sciences Stock (PRAH)